Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 1/20 | 0.67 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.67 |
| ▸ | PPARG | P37231 | 1/20 | 0.66 |
| ▸ | PPARA | Q07869 | 1/20 | 0.66 |
| ▸ | ACE | P12821 | 1/20 | 0.61 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.58 |
| ▸ | ITGB7 | P26010 | 2/20 | 0.58 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.57 |
| ▸ | FPR2 | P25090 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | LDHA | P00338 | 1/20 | 0.55 |
| ▸ | CTSS | P25774 | 6/20 | 0.55 |
| ▸ | CTSK | P43235 | 5/20 | 0.55 |
| ▸ | CTSL | P07711 | 1/20 | 0.54 |
| ▸ | CTSB | P07858 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL335309 | 1.00 | ITGB3 (0.67) | ITGB3ITGA2BPPARGPPARAACE | |
| SCHEMBL1308867 | 1.00 | ITGB3 (0.67) | ITGB3ITGA2BPPARGPPARAACE | |
| SCHEMBL3728960 | 0.96 | ITGB3 (0.64) | ITGB3ITGA2BPPARGPPARAACE | |
| SCHEMBL3728957 | 0.96 | ITGB3 (0.64) | ITGB3ITGA2BPPARGPPARAACE | |
| SCHEMBL8091309 | 0.90 | ITGB3 (0.57) | ITGB3ITGA2BPPARGPPARAACE | |
| SCHEMBL16124030 | 0.90 | ITGB3 (0.57) | ITGB3ITGA2BPPARGPPARAACE | |
| SCHEMBL16228288 | 0.90 | ITGB3 (0.57) | ITGB3ITGA2BPPARGPPARAACE | |
| SCHEMBL16228287 | 0.90 | ITGB3 (0.57) | ITGB3ITGA2BPPARGPPARAACE | |
| SCHEMBL12062761 | 0.90 | ITGB3 (0.57) | ITGB3ITGA2BPPARGPPARAACE | |
| SCHEMBL16228734 | 0.90 | ITGB3 (0.57) | ITGB3ITGA2BPPARGPPARAACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 128 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116874803-A | Antibacterial dendritic polyester polymer and preparation method and application thereof | 清华大学深圳国际研究生院 | 2023-10-13 | — | — | CN | claimed |
| EP-4727552-A2 | PASSIVE PERMEABLE PCSK9 ANTAGONIST COMPOUNDS | Merck Sharp & Dohme LLC (US) | 2026-04-22 | — | — | EP | disclosed |
| WO-2024259310-A2 | PASSIVE PERMEABLE PCSK9 ANTAGONIST COMPOUNDS | MERCK SHARP & DOHME LLC (US) | 2024-12-19 | — | — | WO | disclosed |
| CN-116874803-A | Antibacterial dendritic polyester polymer and preparation method and application thereof | 清华大学深圳国际研究生院 | 2023-10-13 | — | — | CN | disclosed |
| US-20230295613-A1 | LONG CHAIN CARBON AND CYCLIC AMINO ACIDS SUBSTRATES FOR GENETIC CODE REPROGRAMMING | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS | 2023-09-21 | — | — | US | disclosed |
| WO-2023075435-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | 주식회사 베르티스 | 2023-05-04 | — | — | WO | disclosed |
| CN-115867648-A | Extension of chemical substrates for genetic code reprogramming to include long chain carbons and cyclic amino acids | 西北大学 | 2023-03-28 | — | — | CN | disclosed |
| CN-110520413-B | Macrocyclic broad spectrum antibiotics | 阿奇克斯制药公司 | 2023-02-17 | — | — | CN | disclosed |
| CN-108884058-B | Macrocyclic broad spectrum antibiotics | 阿奇克斯制药公司 | 2022-04-29 | — | — | CN | disclosed |
| CN-109219596-B | Macrocyclic broad spectrum antibiotics | 阿奇克斯制药公司 | 2022-04-19 | — | — | CN | disclosed |
| US-7371869-B2 | Substituted hydantoins | HOFFMANN-LA ROCHE INC. (US) | 2008-05-13 | — | — | US | disclosed |
| US-20070197617-A1 | Substituted hydantoins | CHEN SHAOQING | 2007-08-23 | — | — | US | disclosed |
| CN-1839150-A | Lipopeptide antibacterial derivative composition and application method thereof | MIGENIX INC (CA) | 2006-09-27 | — | — | CN | disclosed |
| US-20060063814-A1 | Substituted hydantoins | GOODNOW ROBERT A JR | 2006-03-23 | — | — | US | disclosed |
| WO-2002048097-A9 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF PARASITIC INFECTIONS | CORVAS INT INC (US) | 2003-05-08 | — | — | WO | disclosed |
| US-20020107266-A1 | Compounds, compositions and methods for treatment of parasitic infections | DENDREON CORPORATION | 2002-08-08 | — | — | US | disclosed |
| WO-2002048097-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF PARASITIC INFECTIONS | CORVAS INTERNATIONAL, INC. (US) | 2002-06-20 | — | — | WO | disclosed |
| CN-1183770-A | Piperazine derivatives, medicaments containing these compounds, their use and processes for their preparation | THOMAE GMBH DR K (DE) | 1998-06-03 | — | — | CN | disclosed |
| CN-1104634-A | Compounds having sulfamoyl and amidino groups, process for their preparation and pharmaceutical compositions containing them | SANOFI ELF (FR) | 1995-07-05 | — | — | CN | disclosed |
| US-4508645-A | CYCLIC OLIGOPEPTIDE CONTAINING PENICILLAMINE RESIDE | CESKOSLOVENSKA AKADEMIE VED (CS) | 1985-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197617-A1 | Substituted hydantoins | HNMT, HRH3, BRAF | ITGB3 4777/4885ITGA2B 4740/4885PPARG 2696/4885 |
| US-20020107266-A1 | Compounds, compositions and methods for treatment of parasitic infections | CAT, CTSA, CTRL | ITGB3 873/4885ITGA2B 2183/4885PPARG 1973/4885 |
| US-20060063814-A1 | Substituted hydantoins | HNMT, MAPK6, KYNU | ITGB3 4727/4885ITGA2B 4585/4885PPARG 2185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.